Amends Proxy for Extension Vote, Revises Share Counts and Extension Payment Terms

summarizeSummary

Drugs Made In America Acquisition Corp. filed an amendment to its definitive proxy statement, updating outstanding share counts, adjusting voting thresholds for its extension and adjournment proposals, and revising the monthly payment terms for extending its business combination deadline.

check_boxKey Events

• Amends Proxy Statement

  Filed an amendment to the definitive proxy statement from April 14, 2026, providing updated information for the upcoming extraordinary general meeting.

• Updates Share Counts and Voting Thresholds

  Revised the number of ordinary shares outstanding to 33,717,143 and adjusted the required public shares for the Extension and Adjournment Proposals, making it slightly easier to pass.

• Revises Extension Payment Terms

  Changed the monthly payment for extending the business combination deadline from $0.02 to "the lesser of $300,000 or $0.04 per non-redeemed Public Share", impacting the cost of extension for the sponsor.

auto_awesomeAnalysis

This amendment provides critical updates to the terms of the upcoming extraordinary general meeting, which is essential for the SPAC to extend its life and complete its proposed merger with Power Analytics Global C. The revision of the monthly extension payment from a fixed $0.02 to "the lesser of $300,000 or $0.04 per non-redeemed Public Share" is particularly significant. While the $300,000 cap offers some protection, the doubling of the per-share cost (if the cap isn't met) could impact the sponsor, especially following the recent 10-K disclosure of a going concern warning and the sponsor's default on financial obligations. Investors should carefully review these updated terms as they directly bear on the company's ability to secure the necessary extension and proceed with its business combination.